The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-.kappa.B, and methods for treating diseases in which activation of NF-.kappa.B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-.kappa.B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.
